Abstract：
BACKGROUND: Metastasis of cancer causes more than 90% of cancer deaths and is severely damaging to human health. In recent years, several studies have linked sarcopenia to shorter survival in patients with metastatic cancer. Several predictive models exist to predict mortality in patients with metastatic cancer, but have reported limited accuracy.
METHODS: We systematically searched Medline, EMBASE, and the Cochrane Library for articles published on or before October 14, 2022. Pooled Hazard Ratio (HR) estimates with 95% confidence intervals (CIs) were calculated using a random effects model. The primary outcome was an increased risk of death or tumor progression in patients with metastatic cancer, which is expressed as progression-free survival (PFS). In addition, we performed subgroup analyses and leave-one-out sensitivity analyses to explore the main sources of heterogeneity and the stability of the results.
RESULTS: Sixteen retrospective cohort studies with 1,675 patients were included in the 888 papers screened. The results showed that sarcopenia was associated with lower progression-free survival (HR = 1.56, 95% CI = 1.19-2.03, I2 = 76.3%, P < 0.001). This result was further confirmed by trim-and-fill procedures and leave-one-out sensitivity analysis.
CONCLUSIONS: This study suggests that sarcopenia may be a risk factor for reduced progression-free survival in patients with metastatic cancer. Further studies are still needed to explain the reason for this high heterogeneity in outcome.
BACKGROUND: CRD42022325910.
METHODS: We systematically searched Medline, EMBASE, and the Cochrane Library for articles published on or before October 14, 2022. Pooled Hazard Ratio (HR) estimates with 95% confidence intervals (CIs) were calculated using a random effects model. The primary outcome was an increased risk of death or tumor progression in patients with metastatic cancer, which is expressed as progression-free survival (PFS). In addition, we performed subgroup analyses and leave-one-out sensitivity analyses to explore the main sources of heterogeneity and the stability of the results.
RESULTS: Sixteen retrospective cohort studies with 1,675 patients were included in the 888 papers screened. The results showed that sarcopenia was associated with lower progression-free survival (HR = 1.56, 95% CI = 1.19-2.03, I2 = 76.3%, P < 0.001). This result was further confirmed by trim-and-fill procedures and leave-one-out sensitivity analysis.
CONCLUSIONS: This study suggests that sarcopenia may be a risk factor for reduced progression-free survival in patients with metastatic cancer. Further studies are still needed to explain the reason for this high heterogeneity in outcome.
BACKGROUND: CRD42022325910.
摘要：
背景：癌症转移导致超过90%的癌症死亡，并严重损害人类健康。近年来,多项研究已将少肌症与转移性癌症患者的生存期缩短联系起来.有几种预测模型可以预测转移性癌症患者的死亡率，但报告准确性有限。
方法：我们系统地搜索了Medline，EMBASE,和Cochrane图书馆在2022年10月14日或之前发表的文章。使用随机效应模型计算具有95%置信区间(CI)的集合危险比(HR)估计值。主要结果是转移性癌症患者的死亡或肿瘤进展风险增加，表示为无进展生存期（PFS）。此外,我们进行了亚组分析和留一敏感性分析,以探索异质性的主要来源和结果的稳定性.
结果：在888篇论文中筛选了16项回顾性队列研究，1,675例患者。结果显示，少肌症与较低的无进展生存期相关（HR=1.56，95％CI=1.19-2.03，I2=76.3％，P<0.001)。这一结果通过修剪和填充程序和留一法敏感性分析得到进一步证实。
结论：这项研究表明，少肌症可能是转移性癌症患者无进展生存期降低的危险因素。仍然需要进一步的研究来解释结果高度异质性的原因。
背景：CRD42022325910.
方法：我们系统地搜索了Medline，EMBASE,和Cochrane图书馆在2022年10月14日或之前发表的文章。使用随机效应模型计算具有95%置信区间(CI)的集合危险比(HR)估计值。主要结果是转移性癌症患者的死亡或肿瘤进展风险增加，表示为无进展生存期（PFS）。此外,我们进行了亚组分析和留一敏感性分析,以探索异质性的主要来源和结果的稳定性.
结果：在888篇论文中筛选了16项回顾性队列研究，1,675例患者。结果显示，少肌症与较低的无进展生存期相关（HR=1.56，95％CI=1.19-2.03，I2=76.3％，P<0.001)。这一结果通过修剪和填充程序和留一法敏感性分析得到进一步证实。
结论：这项研究表明，少肌症可能是转移性癌症患者无进展生存期降低的危险因素。仍然需要进一步的研究来解释结果高度异质性的原因。
背景：CRD42022325910.
